Financial Partners

The Canadian Cohort Obstructive Lung Disease (CanCOLD) study is funded by the CIHR (CIHR/ Rx&D Collaborative Research Program Operating Grants- 93326); the Canadian Respiratory Research Network (CRRN); the Respiratory Health Network of the FRSQ; industry partners: Almirall; Astra Zeneca Canada Ltd; Boehringer Ingelheim Canada Ltd; GlaxoSmithKline Canada Ltd; Merck; Novartis; Nycomed; Pfizer Canada Ltd; and Theratechnologies.

The project is led by researchers at RI-MUHC Montreal and Icapture Centre Vancouver.

The Canadian Respiratory Research Network (CRRN) is supported by grants from the Canadian Institutes of Health Research (CIHR) - Institute of Circulatory and Respiratory Health; Canadian Lung Association (CLA)/Canadian Thoracic Society (CTS); British Columbia Lung Association; and Industry Partners Boehringer-Ingelheim Canada Ltd, AstraZeneca Canada Inc., and Novartis Canada Ltd. Funding for training of graduate students and new investigators within the network was supported by the above funding Sponsors and as well by GlaxoSmithKline Inc. The funders had no role in the study design, data collection and analysis, or preparation of the manuscript.


Partenaires publiques


Industry Funding